JP2024519449A - がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用 - Google Patents

がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用 Download PDF

Info

Publication number
JP2024519449A
JP2024519449A JP2023563934A JP2023563934A JP2024519449A JP 2024519449 A JP2024519449 A JP 2024519449A JP 2023563934 A JP2023563934 A JP 2023563934A JP 2023563934 A JP2023563934 A JP 2023563934A JP 2024519449 A JP2024519449 A JP 2024519449A
Authority
JP
Japan
Prior art keywords
antibody
subject
dose
administered
galectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519449A5 (https=
Inventor
フィリポヴィッチ，アレクサンドラ
エレンコ，エリック
ペイドン，ヘザー
コース，クリストファー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puretech LYT Inc
Original Assignee
Puretech LYT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech LYT Inc filed Critical Puretech LYT Inc
Publication of JP2024519449A publication Critical patent/JP2024519449A/ja
Publication of JP2024519449A5 publication Critical patent/JP2024519449A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023563934A 2021-04-30 2022-04-29 がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用 Pending JP2024519449A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163182519P 2021-04-30 2021-04-30
US63/182,519 2021-04-30
US202163193381P 2021-05-26 2021-05-26
US63/193,381 2021-05-26
US202263313882P 2022-02-25 2022-02-25
US63/313,882 2022-02-25
PCT/US2022/027142 WO2022232653A1 (en) 2021-04-30 2022-04-29 Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy

Publications (2)

Publication Number Publication Date
JP2024519449A true JP2024519449A (ja) 2024-05-14
JP2024519449A5 JP2024519449A5 (https=) 2025-05-09

Family

ID=83847357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563934A Pending JP2024519449A (ja) 2021-04-30 2022-04-29 がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用

Country Status (8)

Country Link
US (1) US20240182583A1 (https=)
EP (1) EP4329808A4 (https=)
JP (1) JP2024519449A (https=)
AU (1) AU2022264597A1 (https=)
CA (1) CA3217833A1 (https=)
IL (1) IL308020A (https=)
WO (1) WO2022232653A1 (https=)
ZA (1) ZA202309774B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7581238B2 (ja) * 2019-05-01 2024-11-12 ニューヨーク・ユニバーシティ 抗ガレクチン９抗体およびその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020223702A1 (en) * 2019-05-01 2020-11-05 New York University Anti-galectin-9 antibodies and uses thereof
WO2021022256A1 (en) * 2019-08-01 2021-02-04 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020223702A1 (en) * 2019-05-01 2020-11-05 New York University Anti-galectin-9 antibodies and uses thereof
WO2021022256A1 (en) * 2019-08-01 2021-02-04 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
JP7703513B2 (ja) * 2019-08-01 2025-07-07 ニューヨーク・ユニバーシティ 抗ガレクチン９抗体と化学療法剤の組合せがん治療

Also Published As

Publication number Publication date
US20240182583A1 (en) 2024-06-06
EP4329808A4 (en) 2025-03-12
ZA202309774B (en) 2024-12-18
EP4329808A1 (en) 2024-03-06
AU2022264597A9 (en) 2023-11-16
AU2022264597A1 (en) 2023-11-09
CA3217833A1 (en) 2022-11-03
IL308020A (en) 2023-12-01
WO2022232653A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
AU2020319899B2 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
JP7581238B2 (ja) 抗ガレクチン９抗体およびその使用
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
EP4232089A1 (en) Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma
US20240109968A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
US20240182583A1 (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
US20240190970A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
JP2025522729A (ja) ガレクチン－９を阻害する抗体を用いた悪性血液疾患の処置
HK40108543A (zh) 在癌症疗法中使用的抗半乳糖凝集素-9抗体和化疗剂的组合
US20250269019A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
CN117580589A (zh) 在癌症疗法中使用的抗半乳糖凝集素-9抗体和化疗剂的组合
CN117500522A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
HK40074716A (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
HK40109234A (zh) 用於治疗癌症的方法和组合物
HK40112915A (zh) 抗半乳糖凝集素-9抗体及其治疗用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260327